vs
FrontView REIT, Inc.（FVR）与ARS Pharmaceuticals, Inc.（SPRY）财务数据对比。点击上方公司名可切换其他公司
ARS Pharmaceuticals, Inc.的季度营收约是FrontView REIT, Inc.的1.5倍（$28.1M vs $18.2M），FrontView REIT, Inc.净利率更高（2.2% vs -147.1%，领先149.3%），FrontView REIT, Inc.同比增速更快（12.0% vs -67.6%）
ARS Pharmaceuticals是一家处于后期研发阶段的生物制药企业，专注于开发和商业化严重过敏反应创新疗法，核心产品为无需注射的肾上腺素鼻腔递送制剂，主要面向北美市场，服务存在致命过敏风险的成人及儿童患者群体。
FVR vs SPRY — 直观对比
营收规模更大
SPRY
是对方的1.5倍
$18.2M
营收增速更快
FVR
高出79.5%
-67.6%
净利率更高
FVR
高出149.3%
-147.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.2M | $28.1M |
| 净利润 | $400.0K | $-41.3M |
| 毛利率 | — | — |
| 营业利润率 | 24.9% | -147.6% |
| 净利率 | 2.2% | -147.1% |
| 营收同比 | 12.0% | -67.6% |
| 净利润同比 | — | -182.8% |
| 每股收益（稀释后） | — | $-0.41 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FVRSPRY
| Q1 26 | $18.2M | — | ||
| Q4 25 | $16.5M | $28.1M | ||
| Q3 25 | $16.8M | $32.5M | ||
| Q2 25 | $17.6M | $15.7M | ||
| Q1 25 | $16.2M | $8.0M | ||
| Q4 24 | — | $86.6M | ||
| Q3 24 | $14.5M | $2.1M | ||
| Q2 24 | — | $500.0K |
净利润FVRSPRY
| Q1 26 | $400.0K | — | ||
| Q4 25 | $-4.1M | $-41.3M | ||
| Q3 25 | $4.0M | $-51.2M | ||
| Q2 25 | $-2.9M | $-44.9M | ||
| Q1 25 | $-833.0K | $-33.9M | ||
| Q4 24 | — | $49.9M | ||
| Q3 24 | $-2.4M | $-19.1M | ||
| Q2 24 | — | $-12.5M |
营业利润率FVRSPRY
| Q1 26 | 24.9% | — | ||
| Q4 25 | — | -147.6% | ||
| Q3 25 | — | -163.7% | ||
| Q2 25 | — | -302.9% | ||
| Q1 25 | — | -466.3% | ||
| Q4 24 | — | 54.5% | ||
| Q3 24 | — | -1051.6% | ||
| Q2 24 | — | -3068.0% |
净利率FVRSPRY
| Q1 26 | 2.2% | — | ||
| Q4 25 | -24.9% | -147.1% | ||
| Q3 25 | 23.9% | -157.4% | ||
| Q2 25 | -16.5% | -285.6% | ||
| Q1 25 | -5.1% | -425.7% | ||
| Q4 24 | — | 57.7% | ||
| Q3 24 | -16.7% | -925.0% | ||
| Q2 24 | — | -2503.2% |
每股收益（稀释后）FVRSPRY
| Q1 26 | — | — | ||
| Q4 25 | $-0.19 | $-0.41 | ||
| Q3 25 | $0.19 | $-0.52 | ||
| Q2 25 | $-0.16 | $-0.46 | ||
| Q1 25 | $-0.06 | $-0.35 | ||
| Q4 24 | — | $0.52 | ||
| Q3 24 | — | $-0.20 | ||
| Q2 24 | — | $-0.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $9.3M | $245.0M |
| 总债务越低越好 | — | $96.4M |
| 股东权益账面价值 | $514.2M | $114.3M |
| 总资产 | $869.8M | $327.7M |
| 负债/权益比越低杠杆越低 | — | 0.84× |
8季度趋势，按日历期对齐
现金及短期投资FVRSPRY
| Q1 26 | $9.3M | — | ||
| Q4 25 | $13.5M | $245.0M | ||
| Q3 25 | $19.6M | $288.2M | ||
| Q2 25 | $8.4M | $240.1M | ||
| Q1 25 | $3.3M | $275.7M | ||
| Q4 24 | — | $314.0M | ||
| Q3 24 | — | $204.6M | ||
| Q2 24 | — | $218.7M |
总债务FVRSPRY
| Q1 26 | — | — | ||
| Q4 25 | $314.3M | $96.4M | ||
| Q3 25 | $307.1M | $96.2M | ||
| Q2 25 | $316.9M | — | ||
| Q1 25 | $310.2M | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益FVRSPRY
| Q1 26 | $514.2M | — | ||
| Q4 25 | $391.2M | $114.3M | ||
| Q3 25 | $385.2M | $147.7M | ||
| Q2 25 | $369.9M | $192.3M | ||
| Q1 25 | $324.7M | $229.0M | ||
| Q4 24 | — | $256.8M | ||
| Q3 24 | $1.0K | $201.0M | ||
| Q2 24 | — | $215.2M |
总资产FVRSPRY
| Q1 26 | $869.8M | — | ||
| Q4 25 | $854.4M | $327.7M | ||
| Q3 25 | $846.8M | $372.8M | ||
| Q2 25 | $856.5M | $313.5M | ||
| Q1 25 | $860.8M | $327.3M | ||
| Q4 24 | — | $351.2M | ||
| Q3 24 | $1.0K | $217.6M | ||
| Q2 24 | — | $222.0M |
负债/权益比FVRSPRY
| Q1 26 | — | — | ||
| Q4 25 | 0.80× | 0.84× | ||
| Q3 25 | 0.80× | 0.65× | ||
| Q2 25 | 0.86× | — | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-43.5M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流FVRSPRY
| Q1 26 | — | — | ||
| Q4 25 | $42.1M | $-43.5M | ||
| Q3 25 | $8.3M | $-47.0M | ||
| Q2 25 | $9.3M | $-39.6M | ||
| Q1 25 | $8.1M | $-40.7M | ||
| Q4 24 | — | $42.0M | ||
| Q3 24 | — | $-14.5M | ||
| Q2 24 | — | $-7.3M |
自由现金流FVRSPRY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $-47.2M | ||
| Q2 25 | — | $-39.6M | ||
| Q1 25 | — | $-40.8M | ||
| Q4 24 | — | $41.7M | ||
| Q3 24 | — | $-14.6M | ||
| Q2 24 | — | $-7.3M |
自由现金流率FVRSPRY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | -145.4% | ||
| Q2 25 | — | -252.2% | ||
| Q1 25 | — | -512.1% | ||
| Q4 24 | — | 48.2% | ||
| Q3 24 | — | -706.3% | ||
| Q2 24 | — | -1463.4% |
资本支出强度FVRSPRY
| Q1 26 | — | — | ||
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.6% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 1.1% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 6.8% | ||
| Q2 24 | — | 7.6% |
现金转化率FVRSPRY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.06× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.84× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FVR
暂无分部数据
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
